Get started
Author

Jens Rengelshausen

Observed names: J RENGELSHAUSEN, J Rengelshausen, J. Rengelshausen, Rengelshausen J, Rengelshausen, Jens
Observed institutions: St. Jude Children's Research Hospital, Center for Global Development, German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, Essen University Hospital, Universitätsklinikum Aachen, University of Göttingen, RWTH Aachen University, Grünenthal Group (Germany)
ORCID: 0000-0002-6344-1888
Observed ORCID: 0000-0002-6344-1888
OpenAlex ID: A5013741376
CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
2008 · Johanna Weiss, Magdalena Maria ten Hoevel, et al. · The Journal of Clinical Pharmacology · 208
Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir
2006 · G MIKUS, V SCHOWEL, et al. · Clinical Pharmacology & Therapeutics · 157
Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin–clarithromycin interaction
2003 · Jens Rengelshausen, Christoph Göggelmann, et al. · British Journal of Clinical Pharmacology · 146
PDF
Opposite effects of short-term and long-term St John’s wort intake on voriconazole pharmacokinetics
2005 · J RENGELSHAUSEN, M BANFIELD, et al. · Clinical Pharmacology & Therapeutics · 139
Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine
2006 · Peter E Meissner, Germain Mandi, et al. · Malaria Journal · 127
PDF
High absolute bioavailability of methylene blue given as an aqueous oral formulation
2008 · Ingeborg Walter-Sack, Jens Rengelshausen, et al. · European Journal of Clinical Pharmacology · 107
Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria
2004 · Jens Rengelshausen, J�rgen Burhenne, et al. · European Journal of Clinical Pharmacology · 83
Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]
2005 · Peter E Meissner, Germain Mandi, et al. · Malaria Journal · 63
PDF
Quantification of cationic anti-malaria agent methylene blue in different human biological matrices using cation exchange chromatography coupled to tandem mass spectrometry
2008 · Jürgen Burhenne, Klaus-Dieter Riedel, et al. · Journal of Chromatography B · 57
Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso
2005 · Germain Mandi, Steffen Witte, et al. · Tropical Medicine & International Health · 55
Who is a ‘healthy subject’?—consensus results on pivotal eligibility criteria for clinical trials
2017 · Kerstin Breithaupt-Groegler, Christoph Coch, et al. · European Journal of Clinical Pharmacology · 44
PDF
Effects of Acetaminophen, Naproxen, and Acetylsalicylic Acid on Tapentadol Pharmacokinetics: Results of Two Randomized, Open‐Label, Crossover, Drug‐Drug Interaction Studies
2009 · Johan W. Smit, Charles Oh, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 44
Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations
2013 · Karin Göhler, Martin Brett, et al. · International Journal of Clinical Pharmacology and Therapeutics · 34
Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis
2002 · Jens Rengelshausen, William E. Hull, et al. · American Journal of Kidney Diseases · 32
Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management?
2004 · Meret Martin-Facklam, Jens Rengelshausen, et al. · European Journal of Clinical Pharmacology · 29
A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects
2010 · C. Oh, J. Rengelshausen, et al. · International Journal of Clinical Pharmacology and Therapeutics · 26
How to Interpret an Investigator’s Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum
2021 · Jens Rengelshausen, Kerstin Breithaupt-Groegler, et al. · Therapeutic Innovation & Regulatory Science · 16
PDF
Successful treatment with voriconazole of Aspergillus brain abscess in a boy with medulloblastoma
2005 · M. Stiefel, T. Reiß, et al. · Pediatric Blood & Cancer · 16
Metabolic activation of WHO-congeners PCB28, 52, and 101 by human CYP2A6: evidence from in vitro and in vivo experiments
2024 · Isabella Randerath, Thomas Schettgen, et al. · Archives of Toxicology · 15
PDF
Nutrimetric Validation of Solanidine as Dietary‐Derived CYP2D6 Activity Marker In Vivo
2023 · Julian Peter Müller, Jens Sarömba, et al. · Clinical Pharmacology & Therapeutics · 14
PDF
ADME transcriptome in Hispanic versus White donor livers: Evidence of a globally enhanced NR1I3 (CAR, constitutive androstane receptor) gene signature in Hispanics
2006 · D. Finkelstein, V. Lamba, et al. · Xenobiotica · 14
Inhibition of the human organic anion transporter 1 by the caffeine metabolite 1-methylxanthine
2004 · Jens Rengelshausen, Heike Lindenmaier, et al. · Biochemical and Biophysical Research Communications · 14
Ten years after: findings from the medical surveillance program on Health Effects in High-Level Exposure to PCB (HELPcB)
2023 · Jens Rengelshausen, Isabella Randerath, et al. · Archives of Toxicology · 10
PDF
Decolonization of methicillin-resistant Staphylococcus aureus by disinfection of the skin
2000 · Jens Rengelshausen, Jens Nürnberger, et al. · The American Journal of Medicine · 10
PDF
Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very w gestational age
2006 · Jens Rengelshausen, Bernd Beedgen, et al. · European Journal of Clinical Pharmacology · 8
Works count: 51
Citation count: 1,503
H-index: 16
I10-index: 24
Year
Topic
Type